In the last trading session, 1.63 million shares of the Atara Biotherapeutics Inc (NASDAQ:ATRA) were traded, and its beta was 0.69. Most recently the company’s share price was $0.66, and it changed around -$0.03 or -4.44% from the last close, which brings the market valuation of the company to $78.90M. ATRA currently trades at a discount to its 52-week high of $3.06, offering almost -363.64% off that amount. The share price’s 52-week low was $0.20, which indicates that the current value has risen by an impressive 69.7% since then. We note from Atara Biotherapeutics Inc’s average daily trading volume that its 3-month average coming to 2.72 million.
Atara Biotherapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 2.60. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 1 recommended ATRA as a Hold, whereas 1 deemed it a Buy, and 1 rated it as Underweight. Atara Biotherapeutics Inc is expected to report earnings per share of $Atara Biotherapeutics, Inc. for the current quarter.
Atara Biotherapeutics Inc (NASDAQ:ATRA) trade information
Instantly ATRA has showed a red trend with a performance of -4.44% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently up 28.90% year-to-date, but still down -6.64% over the last five days. On the other hand, Atara Biotherapeutics Inc (NASDAQ:ATRA) is -8.19% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 78.0% from its current value. Analyst projections state that ATRA is forecast to be at a low of $3 and a high of $3.
Atara Biotherapeutics Inc (ATRA) estimates and forecasts
Atara Biotherapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -55.64 percent over the past six months and at a 50.19% annual growth rate that is well above the industry average of 13.30%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 13.12%.
ATRA Dividends
Atara Biotherapeutics Inc’s next quarterly earnings report is expected to be released in May.
